CRIS Connect - Advancing Cell, Tissue and Gene Therapy Products (CTGTPs) in Singapore: Clinical Translation and Clinical Care
Topics
Webinars
15 May 2026
Join leading experts as they discuss emerging trends in cell therapy, CAR-T treatments, and the future of cell and gene therapies in Singapore and beyond.
Registration is now closed.
_Page_1.jpg)
🧪 What is the future of cell therapy in treatment of degenerative diseases and cancer?
Global population ageing is increasing the prevalence of degenerative diseases, whilst there is an increasing trend of early-onset cancer in younger adults. Hence, cell, tissue and gene therapy products (CTGTPs) have come to the fore as new possible therapeutic options for rare diseases, cancer and age‑related conditions.
✨ Join us for our upcoming CRIS Connect webinar, featuring Adj A/Prof Eng Soo Yap (opens in new tab), Chief Medical Officer and Dr Esther Chan (opens in new tab), Deputy Medical Officer, Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) (opens in new tab) as they discuss emerging innovations in cell engineering, Singapore’s regulatory and manufacturing readiness, as well as ACTRIS’ role in advancing the next wave of cell therapy.
Date: Mon, 25 May 2026
Time: 1pm - 2pm
Mode: Online via Zoom
Register here today: https://for.sg/crisconnect (opens in new tab)
🔬 The webinar will also explore the evolving clinical landscape of CAR-T therapies, including emerging indications and practical considerations in the management of patients receiving CAR-T treatment. The session will be moderated by A/Prof Aloysius Ho (opens in new tab), Executive Director of ACTRIS.
CRIS Connect is a monthly webinar series organised by Singapore Clinical Research Institute (SCRI) (opens in new tab) and supported by our programmes and their ecosystem partners.
Find out how our collective effort is advancing national-level R&D initiatives such as: the clinical trials ecosystem, healthcare innovation and clinical adoption, precision medicine, cancer and cardiovascular research programmes, as well as cell therapy manufacturing.

_Page_2.jpg)